Biosense Webster Showcases Cutting Edge Innovation at Boston AF 2013

  Biosense Webster Showcases Cutting Edge Innovation at Boston AF 2013

Business Wire

DIAMOND BAR, Calif. -- January 18, 2013

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of
cardiac arrhythmias, will showcase its portfolio of cutting edge innovative
technologies at the 2013 Boston AF meeting. Boston AF, now in its 18^th year,
provides a scientific forum for health care professionals to learn about
advances in research and therapeutics in the field of atrial fibrillation.

At the meeting, Biosense Webster will showcase its complete portfolio of
market-leading technologies and present an array of innovative solutions for
Electrophysiologists and Allied Health Professionals including:– Clinical
Support, Global Education and Training Programs, Technical Service, Patient
Education, and other resources to support the expanded access to ablation


The new CARTOALARA^™ Module for the company’s CARTO^® 3 System will be
introduced at Boston AF. The CARTOALARA^™ Module seamlessly combines a
fluoroscopy image and CARTO^® 3 System maps into a single view and helps lower
fluoroscopy levels to as low as reasonably achievable. Complementing the
accuracy of the CARTO^® System proprietary magnetic navigation technology, the
CARTOALARA^™ Module is an open architecture technology designed to work with a
variety of industry leading fluoroscopy systems allowing customers to convert
many of their legacy systems with minimal effort.

“This new advance allows electrophysiologists to navigate with confidence from
one integrated view,” said Shlomi Nachman, Worldwide President, Biosense
Webster. “The safety of our physician customers and their patients is very
important to us and we are leading an industry-wide initiative with the goal
of dramatically reducing fluoroscopy use in the EP lab without compromising

Combined with the CARTO^® System Advanced Catheter Location (ACL) Technology,
Fast Anatomical Mapping (FAM) capability and its CONNECTION OF CHOICE^®
functionality, the CARTOALARA^™ Module adds a new dimension to the CARTO®
System’s established electroanatomical mapping accuracy, reinforcing user
trust and confidence.

The CARTOALARA^™ Module will be commercially available in the United States
and Europe starting in February 2013.

About AF and cardiac ablation

Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause
of stroke among people 65 years and older. Worldwide, it is estimated that 20
million people have AF, yet only ~130,000 are treated with ablation every
year. The public health implications of AF are a growing concern because those
with AF are at an increased risk of morbidity and mortality as well as a
reduced quality of life.

Most patients with AF today are treated with anti-arrhythmic drugs (AADs),
even though about half of them are refractory to these drugs. During cardiac
ablation, energy is delivered through the catheter to those areas of the heart
muscle causing the abnormal heart rhythm. This energy “disconnects” the
pathway of the abnormal rhythm. Cardiac ablation is commonly used for “simple”
arrhythmias, like Wolff-Parkison-White Syndrome and atrioventricular nodal
re-entry tachycardia (AVNRT), and is increasingly being used for more complex
arrhythmias like ventricular tachycardia and atrial fibrillation. THERMOCOOL^®
Navigation Catheters are approved for drug refractory recurrent symptomatic
paroxysmal atrial fibrillation, when used with CARTO^® Systems (excluding

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered EP diagnostic
catheters more than 20 years ago and continues to lead the industry as an
innovative provider of advanced cardiac diagnostic, therapeutic, and mapping
tools. As the leader in EP navigation systems and ablation therapy, Biosense
Webster, Inc. has technology that includes the largest installed base of
cardiac mapping navigation systems worldwide in leading hospitals and teaching
institutions. For more information about Biosense Webster and its products,
please visit: (this site is intended for US visitors

Always verify catheter tip location using fluoroscopy or IC signals and
consult the CARTO^® System User Guide regarding recommendations for
fluoroscopy use.

Biosense Webster, Inc. 2013

5548-2013 01USINTEXT


Biosense Webster, Inc.
Janet Kim
(o) 909 839-7275
(m) 213 215 5737
Sandy Pound
(o) 908 218-2720
(m) 908-432-2829
Press spacebar to pause and continue. Press esc to stop.